EU Cannabinoid Regulations 2026: The Retailer's Country-by-Country Guide

If you sell cannabinoid products across Europe, 2026 is the year the ground moved under you. Three things happened between December 2025 and February 2026 that rewrote the rulebook — the UN placed HHC under international control, EFSA finally published a safe-intake level for CBD, and the Netherlands closed its doors on HHC. Most of what you'll read online was written before any of that.

This guide is built for one person: the retailer or distributor deciding what to order next quarter. We ship to seventeen European markets from warehouses in Czechia, the Netherlands, Portugal and Spain. The country sections below reflect what we actually see at customs, not what a law firm summary says should happen in theory.

TL;DR

1. HHC is now an internationally controlled substance. The UN Commission on Narcotic Drugs placed HHC on Schedule II of the 1971 Convention on Psychotropic Substances, effective 6 December 2025. All 184 signatory states — every EU member state included — are now treaty-bound to restrict HHC to scientific, medical and industrial use (WHO confirmation).

2. EFSA set a provisional safe level for CBD: roughly 2 mg per day. On 9 February 2026, EFSA published 0.0275 mg/kg body weight per day as the provisional safe intake — about 2 mg for a 70 kg adult, with CBD ≥98% purity. Applies to food and food supplements only, not cosmetics.

3. The Netherlands banned HHC. On 28 January 2026, HHC was added to List I of the Opium Act — the hard-narcotics schedule. The last major EU exception is gone. Everything else in this article flows from those three facts.

HHC across Europe in 2026

Last full review: 22 April 2026. Every claim cites a primary source where available. Not legal advice.

Of every cannabinoid in the catalogue, HHC had by far the most regulatory movement in the twelve months to April 2026. Four developments changed the commercial picture completely: the UN CND Schedule II placement on 6 December 2025 (UNODC) which made domestic HHC control a treaty obligation for every EU member state; Germany's sixth NpSG amendment on 2 December 2025 which widened the group clause to catch H4CBD and close HHC structural cousins; the France ANSM Decision of 16 January 2026 which added further cannabinoid derivatives to the stupéfiants list (HHC, HHCP, THCP, H4CBD, H2CBD and HHCPO had already been named in the 2023–2024 waves); and the Netherlands Opium Act List I extension of 28 January 2026, the biggest single commercial event of the year — HHC, HHCP and THCP together moved to the hard-narcotics schedule alongside heroin and MDMA.

The cumulative effect: open-retail HHC is effectively closed across the EU. Belgium operates a licensed pharmaceutical-only framework (Arrêté royal, 24 April 2024). Denmark adds substances by name to List B of the Bekendtgørelse om euforiserende stoffer — the 26 March 2026 Bekendtgørelse 405 added 61 further substances at once. Only two member states — Portugal and Croatia — have no HHC-specific schedule as of April 2026; both are treaty-bound under the December 2025 CND decision. Everywhere else, HHC is prohibited by name or by group clause.

Hover the map for country-level status, date of last change, and source link:

Country notes — what's actually going on in each market

The Netherlands is no longer an HHC exception. On 28 January 2026, HHC, HHCP and THCP moved to Opium Act List I. The 2025 generic designer-drug clause (Opiumwet List IA, in force 1 July 2025) primarily targets Spice-type fully synthetic cannabinoids, so H4CBD as of April 2026 still sits outside an explicit Dutch entry — but that window is narrow and further notifications are expected in 2026. Our NL warehouse continues to handle CBD, CBG, CBN and kratom stock routinely.

France is the most comprehensively named market. The 2023 Conseil d'État ruling opened CBD flower retail; at the same time, the ANSM closed HHC, HHCP, THCP, H4CBD, H2CBD and HHCPO by name across the 2023–2024 waves. The ANSM Decision of 16 January 2026 completed the picture with further cannabinoid derivatives. France is the EU market where the semi-synthetic family is most comprehensively listed — not caught by analogy, but named explicitly. If a French retailer asks for an "HHC alternative," there isn't one legally — the answer is CBD and CBG, with THCa cautiously watched.

Germany bans production and sale but not possession. That asymmetry matters: a customer caught with HHC at a German border won't face criminal prosecution, but the shop that sold it will. Don't read the decriminalisation as a commercial signal. The original HHC/HHCP/THCP ban from 27 June 2024 was strengthened on 2 December 2025 through the sixth NpSG amendment, which added a broader structural-analogue clause — H4CBD, the 9H series and concentrated THCV are all caught under the same group wording. Germany is effectively closed for the entire HHC-family catalogue.

Portugal is a grey market under active enforcement. Portugal has no HHC-specific decree as of April 2026 — INFARMED has not issued guidance and no decreto-lei has been published. But that doesn't mean the market is open. Operation "Portugal Sempre Seguro 2026" began on 2 March 2026 with coordinated ASAE, Judicial Police and Tax Authority raids on hemp shops across the country. We treat Portugal as elevated-risk: orders are accepted, but we document the legal ambiguity in writing to the buyer and flag the enforcement climate.

The rest of the EU is closed for HHC. Austria's NPSV framework (23 March 2023) captures the HHC family through structural-class logic. Denmark adds substances by name to List B (HHC since 3 May 2023). Sweden's Läkemedelsverket scheduled ten further substances on 30 December 2025, Finland's Fimea followed on 29 December 2025. Italy, Spain, Bulgaria (since 9 March 2023), Greece, Poland, Hungary and Czechia all operate full HHC-family bans through named listings or group clauses. Romania's HHC ban entered force on 29 March 2025, with a further reclassification approved on 12 February 2026. Croatia is the last EU member state with no HHC-specific schedule — we expect a Ministry of Health decree in 2026 following the treaty obligation.

CBD, Kratom & other cannabinoids

These compound classes sit on completely different regulatory tracks from HHC. CBD is protected at the EU level by the CJEU's 2020 Kanavape judgment (C-663/18): member states cannot prohibit CBD lawfully produced elsewhere in the Union. CBG, CBN, CBC and the minor cannabinoids are not named in any EU member state's narcotics schedule as of April 2026. The active THC analogues (THCP, THCV, 10-OH-HHC, 10-OH-THC, THC-PO) sit in the same regulatory bucket as HHC and are prohibited in every country that has scheduled the HHC family — this is not a grey-zone category. Separately, the less-active HHC derivatives (H4CBD, the 9H series, THC-B, THC-H, THC-JD, THCa, T8HC, T9HC, THP420) are caught by group or structural-analogue clauses in France, Germany, Austria and Hungary, and sit in a genuine grey zone elsewhere. Kratom follows its own regulatory logic entirely.

CBD (ingestible)

Ingestible CBD sits inside the Novel Food framework (Regulation (EU) 2015/2283). EFSA's February 2026 provisional safe level — 0.0275 mg/kg body weight per day, roughly 2 mg for a 70 kg adult — is the first EU-wide compliance anchor. It applies to CBD of ≥98% purity used as food or food supplements, not to cosmetics or topicals. Products dosing above the figure aren't automatically unlawful but sit on shakier Novel Food ground. Italy has the strictest regime: DM 27 June 2024 moved all oral CBD compositions into pharmacy-only distribution. Romania, Greece and Croatia apply a national ≤0.2% THC threshold. Denmark applies a strict Novel Food interpretation; Sweden has flagged CBD oral for narcotic-risk review at Läkemedelsverket. Of the 200+ Novel Food applications filed since 2019, zero are fully authorised on the Union list. If a vendor claims "Novel Food approved" status, ask for the Union list entry. Browse our wholesale CBD range for oils, capsules and isolates with full COAs.

CBG, CBN, CBC, minor cannabinoids and hemp flower

None of CBG, CBN, CBC, CBDa, CBGa, CBDv, CBT or the other minor phytocannabinoids are scheduled in any EU member state as of April 2026. They fall outside the specific Novel Food limits that constrain CBD, though food-use applications still engage Novel Food where the compound is new to the EU diet. EU-compliant hemp flower remains a full retail category in markets where flower sale is permitted — France (post the 2023 Conseil d'État ruling, ≤0.3% THC), Czechia (up to 1% THC under the 2025 Psychomodulatory Act), Switzerland (up to 1% THC), Austria (regulated as a tobacco substitute). Thresholds of 0.2%–0.3% apply across most other markets.

HHC derivatives and the THC-analogue family

This is the broadest category in the catalogue and it splits into two regulatory buckets — not one. The first bucket — THCP, THCV, 10-OH-HHC, 10-OH-THC and THC-PO — is widely prohibited. These compounds are either explicitly THC-active analogues or direct pro-drugs and are scheduled alongside HHC in almost every country that has taken a position on the HHC family. THCP is named in DE, FR, NL, IT, AT, HU, DK, SE and FI. THCV is structurally THC and is caught by the same group clauses that catch THCP in DE (NpSG), FR (ANSM), AT (NPSV) and HU. 10-OH-HHC and 10-OH-THC were named in several EU schedules during 2024–2025 — the 9H-labelled products replaced them precisely because the 10-OH names triggered scheduling. THC-PO is a phosphate ester pro-drug of THCP and is caught under pro-drug logic wherever THCP itself is scheduled.

The second bucket — H4CBD, the 9H series (9H-HHC, 9H-HHCP, 9H-THC), the less-active THC analogues (THC-B, THC-H, THC-JD, THCa) and further derivatives (T8HC, T9HC, THP420) — is a genuine grey zone. France scheduled THCA in June 2024 and Germany's NpSG structural-analogue clause (widened December 2025) catches H4CBD, the 9H series and concentrated close analogues. Austria's NPSV and Hungary's group clause (15th Constitutional Amendment, April 2025) use similar logic. In most other EU markets these compounds are not named — which does not mean they are permitted, only that no specific decree targets them. Compound-by-compound verification against the destination decree is the only reliable approach.

Kratom

Kratom occupies its own regulatory track. Czechia's Psychomodulatory Substances Act (in force 1 January 2025) is the first dedicated EU framework: licensed specialty-shop distribution, age verification, labelling and quality-control rules. HHC is explicitly excluded from that framework. Belgium and Denmark operate permit-based regimes. Poland, Romania, Hungary, Italy and Sweden are closed markets. Most other EU jurisdictions have no named regulatory category — legal to import and sell in practice, but without positive statutory basis.

Country matrix — where every other compound actually stands

The matrix splits the everything-but-HHC catalogue into two honest regulatory buckets. The controlled THC analogues column (THCP, THCV, 10-OH-HHC, 10-OH-THC, THC-PO) tracks the HHC map closely — wherever HHC is prohibited, these are too. The grey-zone derivatives column (H4CBD, 9H series, THC-B, THC-H, THC-JD, THCa, T8HC, T9HC, THP420) is the genuine unknown: caught by name or group clause in four jurisdictions, genuinely unscheduled everywhere else. CBD oral and kratom are included for completeness.

Column definitions.
Controlled analogues = THCP · THCV · 10-OH-HHC · 10-OH-THC · THC-PO (scheduled alongside HHC in every proactive market).
Grey-zone derivatives = H4CBD · 9H-HHC · 9H-HHCP · 9H-THC · THC-B · THC-H · THC-JD · THCa · T8HC · T9HC · THP420 (caught by group clauses in DE/FR/AT/HU, unscheduled elsewhere).
Legend: 🔴 prohibited · 🟡 regulated (Novel Food / pharmacy-only / permit / THC threshold) · 🟢 permitted under named framework · ⚪ grey zone (not named; enforcement may still apply).

* Enforcement — Portugal is under active enforcement (Operation Portugal Sempre Seguro 2026) despite no HHC-specific schedule.
† Watch — Denmark, Sweden and Finland have proactive national schedules where an explicit listing on the grey-zone derivatives is a plausible next-quarter addition.
Per-market qualifiers on CBD (Italy = pharmacy-only via DM 27.6.2024; Romania/Greece/Croatia = ≤0.2% THC threshold; Denmark = strict Novel Food interpretation; Sweden = narcotic-risk review at Läkemedelsverket). Per-market qualifiers on Kratom (Belgium/Denmark/Finland = permit or Rx; Czechia = Psychomodulatory Substances Act 2025). Full context in the section headings above.

What this means for ordering

Ordering is country-specific. Always. "EU-wide legal" is a phrase to be suspicious of. Novel Food status (CBD) is harmonised; everything else is national. Before placing an order, check the matrix for your shipping destination — not the average of Europe.

Documentation doesn't override scheduling. A Certificate of Analysis from a Czech lab doesn't make a product legal in France. An EU-origin claim doesn't override a national narcotics list. Customs officers check against the destination country's schedule, not the supplier's documentation. If a compound is controlled at destination, the only question is whether your shipment gets routed through the right licensed channels.

Plan for faster regulatory change. The cadence of semi-synthetic cannabinoid bans compressed through 2024–2025. The Netherlands flip in January 2026 was the fastest full market change we've tracked. Retailers who buffer 90 days of stock on a single compound carry real write-down risk. We recommend rolling 30–45 days on novel cannabinoids and diversifying across compound families. Portugal and Croatia are the most likely next-quarter movers; Denmark, Sweden and Finland are the most likely to extend coverage on the derivatives.

FAQ

Methodology

Every regulatory claim links to a primary source where one exists in English, or to the authoritative legal-publication summary where the original is in the national language. EU-level citations lean on EFSA, EUDA, the European Commission and the CJEU. National citations prioritise official gazettes, ministry press releases and named national regulators — ANSM (France), BfArM and BfR (Germany), AEMPS (Spain), Lægemiddelstyrelsen (Denmark), Fimea (Finland), Istituto Superiore di Sanità (Italy). All 17 countries were verified against primary sources on 22 April 2026.

Author

Janosch Weidmann, M.Sc. — Specialist author with a Master's degree in Naturopathy and Complementary Medicine. Focus on cannabinoid compounds and European product regulation. Writes for Canapuff B2B on active-ingredient chemistry, procurement due diligence, and regulatory compliance. View author page.

Disclaimer

This article is a commercial compliance overview written for B2B wholesale customers of Canapuff. It is not legal advice. Regulations change quickly — sometimes within hours. Registered B2B customers can raise order-specific country questions with their account manager through the portal; we'll confirm the current position, flag any pending changes, and route the order through the right licensed channels where that's available.

Order now

If you're a retailer or distributor in one of the seventeen markets above, register for B2B wholesale access to see our full catalogue, pricing, and country-specific shipping availability. We verify every new account manually — expect a call back within one business day.

Browse our wholesale range by compound: CBD, CBG, CBN, H4CBD, HHC family (where legal), THC analogues, Kratom.